FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385705891> ?p ?o ?g. }

• W4385705891 endingPage "104935" @default.
• W4385705891 startingPage "104935" @default.
• W4385705891 abstract "Background Disease-modifying therapies (DMTs) in multiple sclerosis (MS) can be classified according to the efficacy in which they prevent inflammatory activity. To date, there are limited data regarding the use of high-efficacy treatments (HETs) in Latin America (LATAM). We aimed to analyze the use of HETs in Argentina, focusing on the clinical and sociodemographic characteristics of the patients who use these treatments and the changes in the trend of use over the years. Methods A retrospective cohort study was done using the Argentina MS patient registry, RelevarEM. Patients diagnosed with relapsing-remitting MS (RRMS) according to validated diagnostic criteria and under treatment with natalizumab, alemtuzumab, cladribine, rituximab or ocrelizumab were included. Results Out of 2450 RRMS patients under a DMT, 462 (19%) were on HETs. One third of those patients (35%) received HETs as the first treatment. The most frequent reason for switching to HETs was treatment failure to previous DMT (77%). The time from MS diagnosis to the first HET in treatment-naive patients was less than one year (IQR: 0-1 year) and in treatment-experienced patients it was 5 years (IQR: 3-9 years). Between 2015 and 2017 (P1), 729 patients included in RelevarEM started a new treatment, of which 85 (11.65%) were HETs. Between 2018 and 2020 (P2), 961 patients included in RelevarEM started a new treatment, of which 284 (29.55%) were HETs. When comparing P2 with P1, a significant increase in the use of HETs was observed (p < 0.01). The most frequently used HETs were alemtuzumab (50.59%) in P1, and cladribine (45.20%) in P2. Conclusion The demographic and clinical characteristics of patients under HET in Argentina were identified. Based on a real-world setting, we found a significant trend towards and a rapid increase in the use of HETs in clinical practice in patients with RRMS." @default.
• W4385705891 created "2023-08-10" @default.
• W4385705891 creator A5005673479 @default.
• W4385705891 creator A5007575849 @default.
• W4385705891 creator A5008547396 @default.
• W4385705891 creator A5020037439 @default.
• W4385705891 creator A5021427387 @default.
• W4385705891 creator A5024208673 @default.
• W4385705891 creator A5027171153 @default.
• W4385705891 creator A5028668873 @default.
• W4385705891 creator A5029651525 @default.
• W4385705891 creator A5030272623 @default.
• W4385705891 creator A5031238764 @default.
• W4385705891 creator A5033974288 @default.
• W4385705891 creator A5036236307 @default.
• W4385705891 creator A5036278441 @default.
• W4385705891 creator A5037757305 @default.
• W4385705891 creator A5041875047 @default.
• W4385705891 creator A5042194104 @default.
• W4385705891 creator A5042670252 @default.
• W4385705891 creator A5051109514 @default.
• W4385705891 creator A5052232552 @default.
• W4385705891 creator A5053251374 @default.
• W4385705891 creator A5053448786 @default.
• W4385705891 creator A5058313039 @default.
• W4385705891 creator A5059692404 @default.
• W4385705891 creator A5059829761 @default.
• W4385705891 creator A5062124748 @default.
• W4385705891 creator A5062498993 @default.
• W4385705891 creator A5066346532 @default.
• W4385705891 creator A5074133959 @default.
• W4385705891 creator A5074852576 @default.
• W4385705891 creator A5080256315 @default.
• W4385705891 creator A5081701168 @default.
• W4385705891 creator A5090063432 @default.
• W4385705891 date "2023-11-01" @default.
• W4385705891 modified "2023-10-01" @default.
• W4385705891 title "Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina" @default.
• W4385705891 cites W1975175488 @default.
• W4385705891 cites W1989806530 @default.
• W4385705891 cites W2027065448 @default.
• W4385705891 cites W2123021165 @default.
• W4385705891 cites W2170005161 @default.
• W4385705891 cites W2530203323 @default.
• W4385705891 cites W2555514711 @default.
• W4385705891 cites W2777074421 @default.
• W4385705891 cites W2782400869 @default.
• W4385705891 cites W2784268727 @default.
• W4385705891 cites W2870575119 @default.
• W4385705891 cites W2888620891 @default.
• W4385705891 cites W2897332214 @default.
• W4385705891 cites W2910867209 @default.
• W4385705891 cites W2912141387 @default.
• W4385705891 cites W2916478209 @default.
• W4385705891 cites W2947491506 @default.
• W4385705891 cites W3002844089 @default.
• W4385705891 cites W3035504219 @default.
• W4385705891 cites W3048359327 @default.
• W4385705891 cites W3109750801 @default.
• W4385705891 cites W3155041105 @default.
• W4385705891 cites W3160738653 @default.
• W4385705891 cites W3170708887 @default.
• W4385705891 cites W3213676036 @default.
• W4385705891 cites W4211048507 @default.
• W4385705891 cites W4224042873 @default.
• W4385705891 cites W4281392294 @default.
• W4385705891 cites W4281569338 @default.
• W4385705891 cites W4281710026 @default.
• W4385705891 cites W4307582098 @default.
• W4385705891 cites W4308524301 @default.
• W4385705891 cites W4376848271 @default.
• W4385705891 doi "https://doi.org/10.1016/j.msard.2023.104935" @default.
• W4385705891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37634468" @default.
• W4385705891 hasPublicationYear "2023" @default.
• W4385705891 type Work @default.
• W4385705891 citedByCount "0" @default.
• W4385705891 crossrefType "journal-article" @default.
• W4385705891 hasAuthorship W4385705891A5005673479 @default.
• W4385705891 hasAuthorship W4385705891A5007575849 @default.
• W4385705891 hasAuthorship W4385705891A5008547396 @default.
• W4385705891 hasAuthorship W4385705891A5020037439 @default.
• W4385705891 hasAuthorship W4385705891A5021427387 @default.
• W4385705891 hasAuthorship W4385705891A5024208673 @default.
• W4385705891 hasAuthorship W4385705891A5027171153 @default.
• W4385705891 hasAuthorship W4385705891A5028668873 @default.
• W4385705891 hasAuthorship W4385705891A5029651525 @default.
• W4385705891 hasAuthorship W4385705891A5030272623 @default.
• W4385705891 hasAuthorship W4385705891A5031238764 @default.
• W4385705891 hasAuthorship W4385705891A5033974288 @default.
• W4385705891 hasAuthorship W4385705891A5036236307 @default.
• W4385705891 hasAuthorship W4385705891A5036278441 @default.
• W4385705891 hasAuthorship W4385705891A5037757305 @default.
• W4385705891 hasAuthorship W4385705891A5041875047 @default.
• W4385705891 hasAuthorship W4385705891A5042194104 @default.
• W4385705891 hasAuthorship W4385705891A5042670252 @default.
• W4385705891 hasAuthorship W4385705891A5051109514 @default.
• W4385705891 hasAuthorship W4385705891A5052232552 @default.
• W4385705891 hasAuthorship W4385705891A5053251374 @default.

• next